NCT02496104 Habituation's Mechanisms in Preterm and Term Infants
| NCT ID | NCT02496104 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University Hospital, Brest |
| Condition | Habituation, Psychophysiological |
| Study Type | OBSERVATIONAL |
| Enrollment | 70 participants |
| Start Date | 2015-07-09 |
| Primary Completion | 2027-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 70 participants in total. It began in 2015-07-09 with a primary completion date of 2027-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Each year in France, 7 % of newborns are born preterm (before 37 weeks of gestational age (GA)). The investigators called very preterm infants those who were born before 33 weeks of GA. These very preterm infants have a higher risk of developing neurological complications like developmental disabilities or cerebral palsy. To date, early assessment of these infants is difficult and not reliable enough to detect those who are at risks of developing neurological issues. Now, the investigators need to identify earlier these infants to provide them interventions to improve their development (physical therapy for example). Consequently, the investigators are examining a study whose aim is to assess preterm infants habituation. Habituation is the newborn ability to become familiar with new environmental stimulations (noise, light…). This habituation allows the newborn to maintain his sleep even at onset of a noise or light. To study this phenomenon in infants born preterm near to corrected term (around 40 weeks of postnatal GA), will allow us to better understand neurological development of these infants. The investigators plan to compare habituation skills of preterm infants near to their theorical date of birth (40 weeks of GA) to a population of infants born at term. The investigators will also study the link between habituation abilities and sleep quality as well as neurodevelopmental outcome at the corrected age of two years old.
Eligibility Criteria
Inclusion Criteria: * Preterm infants: preterm infants born from 25 weeks to 32 weeks + 6 days of gestation near to 36 weeks of gestation (corrected postnatal age) * Term infants: term newborns with a gestational age between 39 and 41 weeks of gestation at day 3 with an Apgar ≥ 1 at 1 minute of life * For both groups: normal neurological physical examination, written informed consent of the parents Exclusion Criteria: * no malformation or chromosomal abnormality, life threatening disease, administration of morphine or sedatives during the 24 hours before the study, context of maternal drug addiction, deafness, no psychoactive drug or anticonvulsivants during the last month of pregnancy for the term newborns, severe neurological disease
Contact & Investigator
Jean-Michel ROUE, Professor
✉ jean-michel.roue@chu-brest.frJean-Michel ROUE, Professor
PRINCIPAL INVESTIGATOR
CHRU de Brest
Frequently Asked Questions
Who can join the NCT02496104 clinical trial?
This trial is open to participants of all sexes, aged 2 Days or older, up to 10 Weeks, studying Habituation, Psychophysiological. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT02496104 currently recruiting?
Yes, NCT02496104 is actively recruiting participants. Contact the research team at jean-michel.roue@chu-brest.fr for enrollment information.
Where is the NCT02496104 trial being conducted?
This trial is being conducted at Brest, France.
Who is sponsoring the NCT02496104 clinical trial?
NCT02496104 is sponsored by University Hospital, Brest. The principal investigator is Jean-Michel ROUE, Professor at CHRU de Brest. The trial plans to enroll 70 participants.